Guardant Health (NASDAQ:GH – Get Rating) posted its quarterly earnings data on Thursday. The company reported ($2.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.25) by ($1.00), Briefing.com reports. Guardant Health had a negative net margin of 107.20% and a negative return on equity of 62.68%. The company had revenue of $109.14 million for the quarter, compared to the consensus estimate of $105.14 million. During the same quarter last year, the company earned ($0.96) earnings per share. The company’s revenue was up 18.5% compared to the same quarter last year. Guardant Health updated its FY 2022 guidance to EPS.
Guardant Health Price Performance
Guardant Health stock traded up $1.83 during trading hours on Friday, hitting $52.92. 1,883,904 shares of the company traded hands, compared to its average volume of 1,278,413. The firm has a market cap of $5.39 billion, a P/E ratio of -12.84 and a beta of 0.81. The company has a quick ratio of 4.71, a current ratio of 4.87 and a debt-to-equity ratio of 2.13. The firm’s 50-day simple moving average is $44.52 and its two-hundred day simple moving average is $54.80. Guardant Health has a 1-year low of $27.65 and a 1-year high of $133.82.
Wall Street Analysts Forecast Growth
A number of research analysts have recently issued reports on the stock. OTR Global downgraded shares of Guardant Health to a “positive” rating in a research report on Monday. Piper Sandler assumed coverage on shares of Guardant Health in a research report on Thursday, June 2nd. They issued an “overweight” rating and a $65.00 price target on the stock. Finally, Citigroup reduced their price target on shares of Guardant Health from $120.00 to $100.00 in a research report on Friday, May 6th. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Guardant Health currently has a consensus rating of “Buy” and an average target price of $131.73.
Hedge Funds Weigh In On Guardant Health
About Guardant Health
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.
- Get a free copy of the StockNews.com research report on Guardant Health (GH)
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- BJ’s Wholesale Club Stock Has More Room to Grow
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.